© The Author 2006. Published by Oxford University Press.
ARTICLE |
Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome
On behalf of the Melanoma Group of the European Organization for Research and Treatment of Cancer
Affiliations of authors: Departments of Morphology and Molecular Pathology (VW, JJvdO) and Surgery (MS), University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium; Divisions of Functional Genomics (VL, PD, TR, OB), Biostatistics and Epidemiology (SM), Dermatology (MFA), Genetics (GL), Cancer Medicine (TT), Pathology (A. Spatz), and Laboratory of Genetic Instability and Cancer (A. Sarasin), Gustave-Roussy Institute, Villejuif, France; Molecular Pathology Program, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain (SRA); Servicio de Dermatología, Hospital 12 de Octubre, Madrid, Spain (PLOR); Surgery Department, Erasmus University Medical Center, Rotterdam, The Netherlands (AMME)
Correspondence to: Alan Spatz, MD, Department of Pathology, Gustave-Roussy Institute, 94805 Villejuif Cedex, France (e-mail: spatz{at}igr.fr).
Background: Gene expression profiling data for human primary cutaneous melanomas are scarce because of the lack of retrospective collections of frozen tumors. To identify differentially expressed genes that may be involved in melanoma progression and prognosis, we investigated the relationship between gene expression profiles and clinical outcome in a cohort of patients with primary melanoma. Methods: Labeled complementary RNA (cRNA) from each tissue sample was hybridized to a pangenomic 44K 60-mer oligonucleotide microarray. Class comparison and class prediction analyses were performed to identify genes whose expression in primary melanomas was associated with 4-year distant metastasis–free survival among 58 patients with at least 4 years of follow-up, distant metastasis, or death. Results were validated immunohistochemically at the protein level in 176 independent primary melanomas from patients with a median clinical follow-up of 8.5 years. Survival was analyzed with a Cox multivariable model and stratified log-rank test. All statistical tests were two-sided. Results: We identified 254 genes that were associated with distant metastasis–free survival of patients with primary melanoma. These 254 genes include genes involved in activating DNA replication origins, such as minichromosome maintenance genes and geminin. Twenty-three of these genes were studied at the protein level; expression of five (MCM4, P = .002; MCM3, P = .030; MCM6, P = .004; KPNA2, P = .021; and geminin, P = .004) was statistically significantly associated with overall survival in the validation set. In a multivariable Cox model adjusted for tumor thickness, ulceration, age, and sex, expression of MCM4 (hazard ratio [HR] of death = 4.04, 95% confidence interval [CI] = 1.39 to 11.76; P = .010) and MCM6 (HR of death = 7.42, 95% CI = 1.99 to 27.64; P = .003) proteins was still statistically significantly associated with overall survival. Conclusion: We identified 254 genes whose expression was associated with metastatic dissemination of cutaneous melanomas. These genes may shed light on the molecular mechanisms underlying poor prognosis in melanoma patients.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Conway, A. Mitra, R. Jewell, J. Randerson-Moor, S. Lobo, J. Nsengimana, S. Edward, D. S. Sanders, M. Cook, B. Powell, et al. Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free Survival Clin. Cancer Res., November 15, 2009; 15(22): 6939 - 6946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kashani-Sabet, S. Venna, M. Nosrati, J. Rangel, A. Sucker, F. Egberts, F. L. Baehner, J. Simko, S. P.L. Leong, C. Haqq, et al. A Multimarker Prognostic Assay for Primary Cutaneous Melanoma Clin. Cancer Res., November 15, 2009; 15(22): 6987 - 6992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Chahine and G. N. Pierce Therapeutic Targeting of Nuclear Protein Import in Pathological Cell Conditions Pharmacol. Rev., September 1, 2009; 61(3): 358 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gogas, A. M. M. Eggermont, A. Hauschild, P. Hersey, P. Mohr, D. Schadendorf, A. Spatz, and R. Dummer Biomarkers in melanoma Ann. Onc., August 1, 2009; 20(suppl_6): vi8 - vi13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. G. Rothberg, M. B. Bracken, and D. L. Rimm Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis J Natl Cancer Inst, April 1, 2009; 101(7): 452 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. John, M. A. Black, T. T. Toro, D. Leader, C. A. Gedye, I. D. Davis, P. J. Guilford, and J. S. Cebon Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma Clin. Cancer Res., August 15, 2008; 14(16): 5173 - 5180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Kreizenbeck, A. J. Berger, A. Subtil, D. L. Rimm, and B. E. Gould Rothberg Prognostic Significance of Cadherin-Based Adhesion Molecules in Cutaneous Malignant Melanoma Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 949 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Terry, E. B. Shows, and S. R. Wente Crossing the Nuclear Envelope: Hierarchical Regulation of Nucleocytoplasmic Transport Science, November 30, 2007; 318(5855): 1412 - 1416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Elliott, R. A. Scolyer, S. Suciu, S. Lebecque, D. Rimoldi, O. Gugerli, E. Musat, R. N. Sharma, D. Lienard, U. Keilholz, et al. Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma Clin. Cancer Res., July 1, 2007; 13(13): 3825 - 3830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Webb, M. A. Merritt, G. M. Boyle, and A. C. Green Microarrays and Epidemiology: Not the Beginning of the End but the End of the Beginning... Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 637 - 638. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Alonso, L. Tracey, P. Ortiz, B. Perez-Gomez, J. Palacios, M. Pollan, J. Linares, S. Serrano, A. I. Saez-Castillo, L. Sanchez, et al. A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of Metastasis Cancer Res., April 1, 2007; 67(7): 3450 - 3460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schramm, J. Vandesompele, J. H. Schulte, S. Dreesmann, L. Kaderali, B. Brors, R. Eils, F. Speleman, and A. Eggert Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome Clin. Cancer Res., March 1, 2007; 13(5): 1459 - 1465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jaeger, D. Koczan, H.-J. Thiesen, S. M. Ibrahim, G. Gross, R. Spang, and M. Kunz Gene Expression Signatures for Tumor Progression, Tumor Subtype, and Tumor Thickness in Laser-Microdissected Melanoma Tissues Clin. Cancer Res., February 1, 2007; 13(3): 806 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rangel, S. Torabian, L. Shaikh, M. Nosrati, F. L. Baehner, C. Haqq, S. P.L. Leong, J. R. Miller III, R. W. Sagebiel, and M. Kashani-Sabet Prognostic Significance of Nuclear Receptor Coactivator-3 Overexpression in Primary Cutaneous Melanoma J. Clin. Oncol., October 1, 2006; 24(28): 4565 - 4569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Melanoma Signatures Come of Age Journal Watch Dermatology, July 28, 2006; 2006(728): 1 - 1. [Full Text]
|
|